Suppr超能文献

原发灶不明癌与BRAF V600E符合BEACON联合治疗方案:一例病例报告

Cancer of unknown primary and BRAF V600E meeting the BEACON combination: A case report.

作者信息

Maly Marlies, Vanwalleghem Lieve, Van Den Eeckhaut Anja, De Wilde Vincent

机构信息

Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.

Department of Gastroenterology and Hepatology, AZ Sint-Jan, 8000 Bruges, Belgium.

出版信息

Mol Clin Oncol. 2024 Sep 30;21(6):88. doi: 10.3892/mco.2024.2786. eCollection 2024 Dec.

Abstract

The diagnostic work-up of cancer of unknown primary (CUP) is a challenging task; in addition, only a little data on BRAF targeting in CUP are currently available. Traditionally, the identification of favourable and unfavourable CUP subsets directs the choice of treatment. The present article reports the case of a 50-year-old male patient presenting with a BRAF-mutated CUP, a rare and generally unfavourable subset. Based on imaging, immunohistochemistry and a high value of carbohydrate antigen 19-9, an upper gastrointestinal profile was initially presumed. After disease progression on treatment with a first-line platinum-based doublet chemotherapy, a significant response was documented after treatment with the BEACON combination. The present case report highlighted the paradigm shift in diagnosis and treatment of CUP from a histology-based approach to molecular profiling with the introduction of precision medicine.

摘要

未知原发灶癌症(CUP)的诊断性检查是一项具有挑战性的任务;此外,目前关于CUP中BRAF靶向治疗的可用数据很少。传统上,识别有利和不利的CUP亚组指导治疗选择。本文报告了一例50岁男性患者,其患有BRAF突变的CUP,这是一种罕见且通常预后不良的亚组。基于影像学、免疫组织化学和高碳水化合物抗原19-9值,最初推测为上消化道病变。在一线铂类双联化疗治疗后疾病进展,使用BEACON组合治疗后记录到显著反应。本病例报告强调了随着精准医学的引入,CUP的诊断和治疗从基于组织学的方法向分子谱分析的范式转变。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5d4/11462391/c72f4c27047b/mco-21-06-02786-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验